Publications
2024 Publications
Nelson BH, Hamilton P, Phung MT, Milne K, Harris B, Thornton S, Stevens D, Kalaria
S, Singh K, Laumont CM, Moss E, Alimujiang A, Meagher NS, Bolithon A, Fereday S, Kennedy
CJ, Hendley J, Ariyaratne D, Alsop K, Traficante N, Goode EL, Karnezis A, Shen H,
Richardson J, McKinnonDeurloo C, Chase A, Grout B, Doherty JA, Harris HR, Cushing-Haugen
KL, Anglesio M, Heinze K, Huntsman D, Talhouk A, Hanley GE, Alsop J, Jimenez-Linan
M, Pharoah PD, Boros J, Brand AH, Harnett PR, Sharma R, Hecht JL, Sasamoto N, Terry
KL, Karlan B, Lester J, Carney ME, Goodman MT, Hernandez BY, Wilkens LR, Behrens S,
Turzanski Fortner R, Fasching PA, Bisinotto C, Candido Dos Reis FJ, Ghatage P, Köbel
M, Elishaev E, Modugno F, Cook L, Le N, Gentry-Maharaj A, Menon U, García MJ, Rodriguez-Antona
C, Farrington K, Kelemen LE, Kommoss S, Staebler A, Garsed DW, Brenton JD, Piskorz
AM, Bowtell DD, DeFazio A, Ramus SJ, Pike MC, Pearce CL. Immunological and molecular
features of the tumor microenvironment of long-term survivors of ovarian cancer. J
Clin Invest. 2024 Oct 29;134(24):e179501. doi: 10.1172/JCI179501. PMID: 39470729;
PMCID: PMC11645148.
Kaur P, Berchuck A, Chase A, Grout B, Deurloo CM, Pearce LC, Pike MC, Richardson J,
Terry KL, Webb PM, Hanley GE. Metformin use and survival in people with ovarian cancer:
A population-based cohort study from British Columbia, Canada. Neoplasia. 2024 Oct;56:101026.
doi: 10.1016/j.neo.2024.101026. Epub 2024 Jul 6. PMID: 38972207; PMCID: PMC11278019.
Nagle CM, Ibiebele TI, Bandera EV, Cramer D, Doherty JA, Giles GG, Goodman MT, Hanley
GE, Harris HR, Jensen A, Kjaer SK, Lee AW, Milne RL, Qin B, Richardson J, Sasamoto
N, Sieh W, Terry KL, Titus L, Trabert B, Wentzensen N, Wu AH, Berchuck A, Pike M,
Pearce CL, Webb PM. Pre-diagnosis tea and coffee consumption and survival after a
diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
Br J Cancer. 2024 Oct;131(6):1043-1049. doi: 10.1038/s41416-024-02792-7. Epub 2024
Jul 18. PMID: 39026080; PMCID: PMC11405517.
Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS,
Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N, Alsop K, Christie
EL, Kang EY, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Alsop J, Beckmann MW, Boros
J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen
KL, Cybulski C, El-Bahrawy MA, Elishaev E, Erber R, Gayther SA, Gentry-Maharaj A,
Blake Gilks C, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J; AOCS Group; Hernandez
BY, Jakubowska A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Kluz T, Koziak
JM, Kristjansdottir B, Le ND, Lener M, Lester J, Lubiński J, Mateoiu C, Orsulic S,
Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Singh N, Rinda
Soong T, Steed H, Sukumvanich P, Talhouk A, Taylor SE, Vierkant RA, Wang C, Widschwendter
M, Wilkens LR, Winham SJ, Anglesio MS, Berchuck A, Brenton JD, Campbell I, Cook LS,
Doherty JA, Fasching PA, Fortner RT, Goodman MT, Gronwald J, Huntsman DG, Karlan BY,
Kelemen LE, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sundfeldt K, Swerdlow
AJ, Goode EL, DeFazio A, Köbel M, Ramus SJ, Bowtell DDL, Garsed DW. Concurrent RB1
loss and BRCA-deficiency predicts enhanced immunological response and long-term survival
in tubo-ovarian high-grade serous carcinoma. medRxiv [Preprint]. 2023 Nov 10:2023.11.09.23298321.
doi: 10.1101/2023.11.09.23298321. Update in: Clin Cancer Res. 2024 Aug 15;30(16):3481-3498.
doi: 10.1158/1078-0432.CCR-23-3552. PMID: 37986741; PMCID: PMC10659507.
Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C,
Hood BL, Conrads KA, Teng PN, Oliver J, Gist G, Mitchell D, Litzi TJ, Tarney CM, Crothers
BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C,
Meerzaman D, Bodelon C, Wentzensen N, Lee JSH; APOLLO Research Network; Huntsman DG,
Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell DDL, Conrads TP, Maxwell GL. Proteogenomic
analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic
vulnerabilities. NPJ Precis Oncol. 2024 Mar 13;8(1):68. doi: 10.1038/s41698-024-00519-8.
Erratum in: NPJ Precis Oncol. 2024 May 6;8(1):97. doi: 10.1038/s41698-024-00588-9.
PMID: 38480868; PMCID: PMC10937683.
2023 Publications
Heinze K, Cairns ES, Thornton S, et al. The Prognostic Effect of Immune Cell Infiltration
Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas. Clin Cancer Res.
2023 Sep 1;29(17):3471-3483. doi: 10.1158/1078-0432.CCR-22-3815
Kang EY, Weir A, Meagher NS, et al. CCNE1 and survival of patients with tubo-ovarian
high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer.
2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582
2022 Publications
Meagher NS, Hamilton P, Milne K, et al. Profiling the immune landscape in mucinous
ovarian carcinoma. Gynecol Oncol. 2023;168:23-31. doi:10.1016/j.ygyno.2022.10.022
Garsed DW, Pandey A, Fereday S, et al. The genomic and immune landscape of long-term
survivors of high-grade serous ovarian cancer. Nat Genet. 2022;54(12):1853-1864. doi:10.1038/s41588-022-01230-9
Phung MT, Webb PM, DeFazio A, et al. Lifestyle and personal factors associated with
having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Gynecol Oncol. 2023;168:68-75. doi:10.1016/j.ygyno.2022.10.018
Garsed DW, Bowtell DDL. Beating the odds: molecular characteristics of long-term survivors
of ovarian cancer. Nat Genet. 2022 Dec;54(12):1780-1781. doi: 10.1038/s41588-022-01234-5.
PMID: 36456882.
Phung MT, Alimujiang A, Berchuck A, et al. Reproductive Factors Do Not Influence Survival
with Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(4):909-913. doi:10.1158/1055-9965.EPI-21-1091
2021 Publications
Brieger KK, Phung MT, Mukherjee B, et al. High Prediagnosis Inflammation-Related Risk
Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers
Prev. 2022;31(2):443-452. doi:10.1158/1055-9965.EPI-21-0977
Hanley GE, Kaur P, Berchuck A, et al. Cardiovascular medications and survival in people
with ovarian cancer: A population-based cohort study from British Columbia, Canada.
Gynecol Oncol. 2021;162(2):461-468. doi:10.1016/j.ygyno.2021.05.021
2020 Publications
Saner FAM, Herschtal A, Nelson BH, et al. Going to extremes: determinants of extraordinary
response and survival in patients with cancer. Nat Rev Cancer. 2019;19(6):339-348.
doi:10.1038/s41568-019-0145-5
Millstein J, Budden T, Goode EL, et al. Prognostic gene expression signature for high-grade
serous ovarian cancer. Ann Oncol. 2020;31(9):1240-1250. doi:10.1016/j.annonc.2020.05.019
Brieger KK, Peterson S, Lee AW, et al. Menopausal hormone therapy prior to the diagnosis
of ovarian cancer is associated with improved survival. Gynecol Oncol. 2020;158(3):702-709.
doi:10.1016/j.ygyno.2020.06.481
2019 Publications
Minlikeeva AN, Cannioto R, Jensen A, et al. Joint exposure to smoking, excessive weight,
and physical inactivity and survival of ovarian cancer patients, evidence from the
Ovarian Cancer Association Consortium. Cancer Causes Control. 2019;30(5):537-547.
doi:10.1007/s10552-019-01157-3
Clarke CL, Kushi LH, Chubak J, et al. Predictors of Long-Term Survival among High-Grade
Serous Ovarian Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019;28(5):996-999.
doi:10.1158/1055-9965.EPI-18-1324
Alimujiang A, Khoja L, Wiensch A, et al. "I am not a statistic" ovarian cancer survivors'
views of factors that influenced their long-term survival. Gynecol Oncol. 2019;155(3):461-467.
doi:10.1016/j.ygyno.2019.10.007
2018 Publications
Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski
V, Garès V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM,
Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe
K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau
PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome
RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P,
Nelson BH, Bowtell DDL, deFazio A; Nadia Traficante, for the Australian Ovarian Cancer
Study Group. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma
Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian
Cancer. Clin Cancer Res. 2018 Feb 1;24(3):569-580. doi: 10.1158/1078-0432.CCR-17-1621.
Epub 2017 Oct 23. PMID: 29061645.
2017 Publications
Praestegaard C, Jensen A, Jensen SM, et al. Cigarette smoking is associated with adverse
survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.
Int J Cancer. 2017;140(11):2422-2435. doi:10.1002/ijc.30600
Dixon SC, Nagle CM, Wentzensen N, et al. Use of common analgesic medications and ovarian
cancer survival: results from a pooled analysis in the Ovarian Cancer Association
Consortium. Br J Cancer. 2017;116(9):1223-1228. doi:10.1038/bjc.2017.68
Minlikeeva AN, Freudenheim JL, Eng KH, et al. History of Comorbidities and Survival
of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
Cancer Epidemiol Biomarkers Prev. 2017;26(9):1470-1473. doi:10.1158/1055-9965.EPI-17-0367
Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium
Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, et al. Current
Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J
Natl Cancer Inst. 2017;109(10):djx144. doi:10.1093/jnci/djx144
2016 Publications
Cannioto RA, LaMonte MJ, Kelemen LE, et al. Recreational physical inactivity and mortality
in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer
Association Consortium. Br J Cancer. 2016;115(1):95-101. doi:10.1038/bjc.2016.153
2015 Publications
Nagle CM, Dixon SC, Jensen A, et al. Obesity and survival among women with ovarian
cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015;113(5):817-826.
doi:10.1038/bjc.2015.245
